BIOTEST AG
History
| Year | Detail |
|---|---|
| 1946 | Carl Adolf Schleussner and Dr Hans Schleussner under Biotest Serum-Institut GmbH founded Biotest AG. The company initially focused on research on blood typing serology. |
| 1979 | Biotest developed the first air sampler, which started Biotest's Microbiological Diagnostic business (hygiene monitoring). |
| 1986 | Biotest changed its name from Biotest Serum-Institut GmbH to Biotest AG, advancing in the expansion of its Pharmaceutical and Diagnostic business divisions. |
| 1993 | Biotest started producing the first double virus-inactivated factor VIII preparation (Haemoctin) for haemophiliacs. |
| 2011 | Abbott and Biotest AG signed a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for treating rheumatoid arthritis (RA) and psoriasis. |
| 2015 | Biotest AG and Affibody AB entered into a research license and option agreement regarding the Albumod(TM) technology platform. This platform is designed to prolong the duration of action of biopharmaceuticals and, therefore, potentially enhance their efficacy. |
| 2017 | Biotest started a European clinical phase III study in the indication Primary Immune Thrombocytopenia (ITP) of IgG Next Generation, a novel development of our polyvalent immunoglobulin G. |
| 2023 | Grifols and Biotest joined forces in core markets to strengthen their joint position. Biotest sells five distribution companies in Spain, Italy, the UK, France, and Brazil to Grifols in this context. |
BCC Research Beacon 